secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001193125-22-309122
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics sets 2023 base salaries and bonuses for named executives
---------------------------------------------------------------------------

- CEO Azelby: $438,750 2022 bonus; 2023 base $702,000, 65% target bonus (company goals only).
- COO/CFO Lavelle: $209,588 2022 bonus; 2023 base $484,380, 45% target bonus.
- CSO Morisset: £145,467 2022 bonus; 2023 base £336,190, 45% target bonus.
- 2023 company performance goals to be set later by Board; individual goals subjective.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312522309122/0001193125-22-309122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312522309122/d399841d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-309122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer